Shortened Antibiotic Treatment of 5 Days in Community-Acquired Pneumonia
Key facts
- Who runs it
- Thomas Benfield
- Where
- Denmark7 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 395 people enrolled
- Started
- 18 Sept 2019
- Ended
- 22 Jan 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Intervention
- Control
- Record updated
- 3 April 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Hospitalized with community-acquired pneumonia; defined as new pulmonary infiltrate on chest X-ray and/or CT scan and at least one symptom compatible with pneumonia (cough, fever, dyspnoea and/or chest pain)
- Initiation of antibiotics within 12 hours of the time of the chest X-ray with an infiltrate
- Age ≥ 18 years
- Afebrile (temperature ≤ 37.8 °C) for 48 hours at randomization
- Clinically stable at randomization (systolic blood pressure ≥ 90 mm Hg, heart rate ≤ 100/min., respiratory rate ≤ 24/min., peripheral oxygen saturation ≥ 90%)
Who cannot take part
- Hospitalization during the previous 14 days
- Uncommon cause requiring longer duration of antimicrobial therapy (Pseudomonas aeruginosa, Staphylococcus aureus, Mycobacterium spp., fungi)
- Immunosuppression (HIV-positive, neutropenia, corticosteroid treatment (≥10 mg/day of prednisone or the equivalent for >30 days), chemotherapy, immunosuppressive agents, immunosuppressed after solid organ transplantation, asplenia)
- Extrapulmonary infection (e.g. endocarditis, meningitis, or abscess)
- Antibiotic treatment (>2 days) within the past 30 days, directed at lower respiratory tract pathogens
- Pleural empyema or lung abscess
- Pleural effusion requiring drainage tube
- Intensive care unit (ICU) admittance
- Pregnancy and breastfeeding
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
CAP5 is an investigator-initiated multicentre non-inferiority randomized controlled trial which aims to assess the efficacy and safety of shortened antibiotic treatment duration of community-acquired pneumonia (CAP) in hospitalized adult patients based on clinical stability criteria.
Read full original descriptionShow less
Three to five days after initiation of antimicrobial therapy for CAP, participants are randomized 1:1 to parallel treatment arms: 5 days (intervention) or minimum 7 days (control) of antibiotic treatment. The intervention group discontinues antibiotics at day 5 if clinically stable and afebrile for at least 48 hours. The control group receives antibiotics for a duration of 7 days or longer at the discretion of the treating physician.
The primary outcome is 90-day survival which will be tested with a non-inferiority margin of 6%.
The 2 groups in the trial
- Intervention groupTreatment being tested
Shortened antibiotic treatment of 5 days
Treatment: Intervention
- Control groupExisting treatment, for comparison
Antibiotic treatment of 7 days or longer at the discretion of the treating physician
Treatment: Control
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Shortened Antibiotic Treatment in Community-Acquired Pneumonia: A Nationwide Danish Randomized Controlled Trial
- Publications
- Record updated
- 3 April 2025